Eric Putnoi, MD
Ophthalmology · Waltham, MANPI 1538150487
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 538 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations.
Across 538 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$1K
- Oyster Point Pharma, Inc.$1K
- Novartis$737
- Bausch & Lomb Americas Inc.$611
- plus $3K from 21 others
What the payments were for
- Food & beverage$11,00998%
- Education$400%
- Gifts$901%
- Entertainment$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 78 | $2,364 |
| AbbVie(2 entities) | 132 | $2,078 |
| Sun Pharmaceutical Industries Inc. | 66 | $1,450 |
| Oyster Point Pharma, Inc. | 39 | $1,134 |
| Novartis | 43 | $737 |
| Bausch & Lomb Americas Inc. | 33 | $611 |
| Kala Pharmaceuticals, Inc. | 36 | $516 |
| Ocular Therapeutix, Inc. | 27 | $477 |
| Tarsus Pharmaceuticals, Inc. | 11 | $390 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $293 |
| Aerie Pharmaceuticals, Inc. | 16 | $292 |
| Dompe US, Inc. | 4 | $122 |
| Eyevance Pharmaceuticals LLC | 6 | $105 |
| Amgen(2 entities) | 4 | $87 |
| Optos, Inc. | 3 | $85 |
| NEW World Medical,inc. | 6 | $83 |
| Rayner Intraocular Lenses Limited | 4 | $75 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $63 |
| Johnson & Johnson Vision Care, Inc. | 1 | $45 |
| Rxsight Inc | 1 | $42 |
| Shire North American Group Inc | 2 | $41 |
| Sight Sciences, Inc. | 2 | $36 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Thea Pharma Inc. | 1 | $25 |
| Omeros Corporation | 1 | $19 |
| LKC Technologies, Inc. | 1 | $15 |
| Carl Zeiss Meditec, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$284
How this compares
$11,224 in reported general payments places this provider in the 85th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 178 | $239,157 |
| MieboPerfluorohexyloctane/Pf | 91 | $68,730 |
| Cyclosporine | 91 | $58,255 |
| XiidraLifitegrast | 38 | $56,032 |
| LumiganBimatoprost | 80 | $39,273 |
| TyrvayaVarenicline Tartrate | 37 | $24,696 |
| RhopressaNetarsudil Mesylate | 48 | $23,161 |
| RocklatanNetarsudil Mesylat/Latanoprost | 35 | $17,662 |
| Bromfenac Sodium | 53 | $15,728 |
| Prednisolone Acetate | 424 | $14,139 |
| VyzultaLatanoprostene Bunod | 34 | $13,310 |
| CequaCyclosporine | 21 | $12,792 |
| InveltysLoteprednol Etabonate | 22 | $12,262 |
| ProlensaBromfenac Sodium | 16 | $9,284 |
| Latanoprost | 679 | $8,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $2,078 | $278,430258 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $611 | $138,072163 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $292 | $40,82383 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $1,134 | $24,69637 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax, Loteprednol Etabonate | $293 | $16,86551 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,450 | $12,79221 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $516 | $12,26222 claims |
| AlconSimbrinza | $2,364 | $4,12521 claims |
| Eyevance Pharmaceuticals LLCFlarex | $105 | $1,50112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Waltham
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- Jonathan TalamoWaltham$225K
- Nandini VenkateswaranWaltham$149K
- Charles FosterWaltham$24K
- Rishi SinghBoston$1.7M
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.